New Delhi, Feb 19: Yoga guru Baba Ramdev's Patanjali Ayurved on Friday said its Coronil tablet has received certification from the Ayush Ministry as a medicine supporting COVID-19 treatment as per the World Health Organization's certification scheme.

Patanjali also released what it claimed was research work supporting Coronil's efficacy in COVID-19 treatment.

The Union Ayush Ministry had earlier categorised ayurvedic Coronil tablets as an ''Immuno-booster''.

Now, it has been recognised as a medicine for "supporting measure in COVID-19" treatment, Ramdev told reporters at a press conference here.

"Study on the impact of Coronil on COVID has already been published in leading journals," Ramdev said, adding "it would work not only for treatment, prevention and cure of COVID but also help in after-effects."

This is the first company in India which has received such a licence, he claimed.

The announcement regarding the Ayush certification for Coronil and release of a research paper calling it the "first evidence-based medicine for COVID-19 by Patanjali" was done at an event here attended by Union Health Minister Harsh Vardhan and Transport Minister Nitin Gadkari.

In a statement, Patanjali said: "Coronil has received the Certificate of Pharmaceutical Product (CoPP) from the Ayush section of Central Drugs Standard Control Organisation as per the WHO certification scheme."

Under CoPP, Coronil can now be exported to 158 countries, it claimed.

Patanjali had introduced ayurveda-based Coronil on June 23 last year, when the pandemic was at its peak. It had to face severe criticism as it lacked scientific evidence regarding its efficacy.

The Ayush Ministry had classified it as an "Immuno-booster" only.

The ministry earlier this month recognised Coronil as a medicine for "supporting measure in COVID-19" treatment, Ramdev said.

"This certification will remove the misconception about it in people''s mind as it cures COVID also," Ramdev said, adding "it will work against asymptomatic, symptomatic and severe (cases) also. We have data for that."

"It received a huge response despite all controversies. We have data which suggests that more than one crore people have consumed it," he added.

Ramdev further said Coronil will help humanity while providing sustainable and affordable treatment.

"Some people manufacture medicines for their business but we have done it for treatment and welfare of the public (upchar aur upkar ke bhavna se)," he said.

After Coronil, Patanjali now plans to introduce more ayurvedic medicines, backed with scientific evidence and certification, he added.

Patanjali spokesperson S K Tijarawala said Coronil has done business of Rs 500 crore in the last seven months.

Coronil has been developed by Patanjali Research Institute. It had started work on an ayurvedic remedy for COVID-19 in January 2020.

Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.



London, Nov 22: A bomb disposal squad deployed as a “precaution” to the South Terminal of Gatwick Airport concluded an investigation into a "security incident" on Friday after making a “suspect package” safe.

The South Terminal of Gatwick Airport, the UK's second busiest airport after Heathrow, which was briefly shut owing to the incident reopened following the incident.

The Gatwick is around 45 km south of London.

Two people detained during the enquiries have since been allowed to continue their journey as the airport was opened.

“Police have concluded their investigation into a report of a suspect package at Gatwick Airport. Officers from the EOD (Explosive Ordnance Disposal) team made the package safe, and the airport has been handed back to its operator,” Sussex Police said in an updated statement.

“Two people detained while enquiries were ongoing have subsequently been allowed to continue their journeys. There will remain an increased police presence in the area to assist with passengers accessing the South Terminal for onward travel,” the statement added.

Earlier on Friday, the incident caused severe disruption at the busy airport’s South Terminal, while the North Terminal of Gatwick Airport remained unaffected.

“Police were called to the South Terminal at Gatwick Airport at 8.20 am on Friday (November 22) following the discovery of a suspected prohibited item in luggage,” a Sussex Police statement said.

“To ensure the safety of the public, staff and other airport users, a security cordon has been put in place whilst the matter is dealt with. As a precaution, an EOD (Explosive Ordnance Disposal) team is being deployed to the airport. This is causing significant disruption and some roads around the South Terminal have been closed. We’d advise the public to avoid the area where possible,” it said.

Footage on social media taken outside the airport showed crowds of frustrated travellers being moved away from the terminal building.

Gatwick said it was working hard to resolve the issue.

“A large part of the South Terminal has been evacuated as a precaution while we continue to investigate a security incident," the airport said in a social media post.

“Passengers will not be able to enter the South Terminal while this is ongoing. The safety and security of our passengers and staff remain our top priority. We are working hard to resolve the issue as quickly as possible.”

Train and bus services that serve the airport were also impacted while the police carried out their inquiries.

In an unrelated incident in south London on Friday morning, the US Embassy area in Nine Elms by the River Thames was the scene of a controlled explosion by Scotland Yard dealing with what they believe may have been a “hoax device”.

“We can confirm the 'loud bang' reported in the area a short time ago was a controlled explosion carried out by officers,” the Metropolitan Police said in a post on X.

“Initial indications are that the item was a hoax device. An investigation will now follow. Some cordons will remain in place for the time being but the majority of the police response will now be stood down,” it added.